NealShoreMDCPI,FACS

Urology • Murrells Inlet, SC

Managing Partner,Atlantic Urology Clinics Medical Director, Carolina Urologic Research Center

Join to view full profile

Dr. Shore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shore's full profile

Already have an account?

Office
4367 Riverwood Drive
Unit 110
Murrells Inlet, SC 29576
Phone+1 843-357-1066

Fax+1 843-497-6171
Is this information wrong?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1986 - 1990
OtherClass of 1984
Duke University School of MedicineClass of 1983

Certifications & Licensure

SC State Medical License 1994 - 2025
NY State Medical License 1985 - 2008
NJ State Medical License 1990 - 1995
American Board of Urology Urology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACS) American College of Surgeons

Clinical Trials

MCS in the Treatment of Lower Urinary Tract Symptoms Start of enrollment: 2010 Jul 01
Completed
Phase 2, Phase 3
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T Start of enrollment: 2012 Oct 01
Terminated
UroLift System TOlerability and ReCovery When Administering Local Anesthesia Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
Terminated
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 2
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2014 May 26
Completed
Phase 3
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC Start of enrollment: 2013 Aug 01
Completed
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Start of enrollment: 2014 Oct 01
Terminated
Phase 2
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma Start of enrollment: 2014 Aug 01
Completed
Phase 3
PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study Start of enrollment: 2014 Sep 01
Terminated
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Start of enrollment: 2015 Aug 01
Completed
Phase 3
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device Start of enrollment: 2015 Jul 01
Completed
Not Applicable
Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis Start of enrollment: 2015 Sep 23
Completed
Phase 2
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg Start of enrollment: 2016 Feb 01
Completed
Phase 3
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients Start of enrollment: 2016 Dec 01
Completed
Phase 1
Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI Start of enrollment: 2021 Jan 21
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patient...
Fred Saad, Maha H A Hussain, Bertrand Tombal, Karim Fizazi, Cora N Sternberg, E David Crawford, Luke T Nordquist, Martin Bögemann, Ronald Tutrone, Neal D Shore, Lauren...> ;European Urology. 2024 Apr 20
Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance.
Ashley E Ross, Kenneth K Iwata, Dina Elsouda, John Hairston, David Russell, Elai Davicioni, James A Proudfoot, Edward M Schaeffer, Neal D Shore> ;JCO Precision Oncology. 2024 Apr 1
First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in ...
Rana R McKay, Alicia K Morgans, Neal D Shore, Curtis Dunshee, Geeta Devgan, Neeraj Agarwal> ;Cancer Treatment Reviews. 2024 May 1
Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
Mohamad Moussa, Mohamad Abou Chakra, Athanasios Papatsoris, Yasser Farahat, Michael A O'Donnell, Neal D Shore> ;Archivio Italiano Di Urologia, Andrologia. 2024 Mar 19
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...
Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Ro...> ;Clinical Cancer Research. 2024 Mar 15
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Marianne Keessen, Robert Dreicer, Tomas Buchler, Péter F Árkosy, Tibor Csöszi, Pawel Wiechno, Evgeny Kopyltsov, Sergey V Orlov, Alexey Plekhanov, Maria Smagina, Sergei...> ;European Journal of Cancer. 2024 May 1
Complications of immuno-oncology care: what urologist should know.
Valentina Grajales, Alberto Martini, Neal D Shore> ;BJU International. 2024 May 1
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore, N., Gratzke, C., Feyerabend, S., Werbrouck, P., Carles, J., Vjaters, E., Tammela, T., Morris, D., Aragon-Ching, J., Concepcion, R., Emmenegger, U., Fleshner, N....> ;The Oncologist. 2024 Feb 23
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A., De Giorgi, U., Joung, J., Fong, P., Voog, E., Jones, R., Shore, N., Dunshee, C., Zschäbitz, S., Oldenburg, J....> ;Nature Medicine. 2024 Jan 31
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer.
Pienta, K., Moul, J., Shore, N., Czernin, J., King, M., Freedland, S.> ;Prostate Cancer and Prostatic Diseases. 2024 Jan 17
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Gary D Steinberg, Neal D Shore, Joan Palou Redorta, Matthew D Galsky, Jens Bedke, Ja Hyeon Ku, Michal Kretkowski, Hailong Hu, Konstantin Penkov, Jennifer J Vermette, J...> ;Future Oncology. 2024 May 1
Updates on Management of Biochemical Recurrent Prostate Cancer.
Cooley, L., Srivastava, A., Shore, N.> ;Current Treatment Options in Oncology. 2024 Mar 1
Mechanism of action of nadofaragene firadenovec-vncg.
Jørn S Jakobsen, Vikram M Narayan, Joshua J Meeks, Neal D Shore, Grannum R Sant, Badrinath R Konety> ;Frontiers in Oncology. 2024 Jan 1
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Saad, F., Tombal, B., Saltzstein, D., Hanson, S., Brown, B., Lu, S., Fallick, M., Tutrone, R., George, D., Bailen, J., Cookson, M., Shore, N.> ;European Urology Oncology. 2023 Dec 23
Interruptions in bladder cancer care during the COVID-19 public health emergency.
John L Gore, Kristin Follmer, Jason Reynolds, Michael Nash, Christopher B Anderson, James W F Catto, Karim Chamie, Siamak Daneshmand, Rian Dickstein, Tullika Garg, Sco...> ;Urologic Oncology. 2024 Apr 1
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga, F., Azad, A., Iguchi, T., Villers, A., Alcaraz, A., Alekseev, B., Rosbrook, B., Zohren, F., Ma, J., Haas, G., Stenzl, A., Szmulewitz, R., Holzbeierlein, J...> ;European Urology Oncology. 2023 Dec 9
5 citations
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A., De Giorgi, U., Joung, J., Fong, P., Voog, E., Jones, R., Shore, N., Dunshee, C., Zschäbitz, S., Oldenburg, J....> ;Nature Medicine. 2024 Jan 1
1 citations
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.
Freedland, S., Gleave, M., De Giorgi, U., Rannikko, A., Pieczonka, C., Tutrone, R., Venugopal, B., Woo, H., Ramirez-Backhaus, M., Supiot, S., Lantz, A., Ganguli, A., I...> ;NEJM Evidence. 2023 Dec 1
3 citations
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations inand/orin the PROfound Trial.
Joaquin Mateo, Johann S de Bono, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Mustafa Özgüro...> ;Journal of Clinical Oncology. 2024 Feb 10
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 ...
Evan Y Yu, William R Berry, Howard Gurney, Margitta Retz, Henry J Conter, Brigitte Laguerre, Peter C C Fong, Cristiano Ferrario, Tilman Todenhöfer, Gwenaelle Gravis, J...> ;European Urology Oncology. 2023 Nov 6
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Robert Hugh Jones, Karim Fizazi, Nicholas D James, Teuvo L Tammela, Nobuaki Matsubara, Frank Priou, Philippe Beuzeboc, Thierry Lesimple, Petri Bono, Vesa Kataja, Jorge...> ;Prostate Cancer and Prostatic Diseases. 2023 Oct 26
2 citations
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Neeraj Agarwal, Fred Saad, Arun A Azad, Joaquin Mateo, Nobuaki Matsubara, Neal D Shore, Jayeta Chakrabarti, Hsiang-Chun Chen, Silvana Lanzalone, Alexander Niyazov, Kar...> ;Future Oncology. 2024 Mar 1
2 citations
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Bertrand Tombal, Sean Collins, Alicia K Morgans, Elke Hunsche, Bruce Brown, Emily Zhu, Alberto Bossi, Neal Shore> ;European Urology. 2023 Dec 1
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Neal D Shore, Maha Hussain, Fred Saad, Karim Fizazi, Cora N Sternberg, David Crawford, Bertrand Tombal, Michael Cookson, Frank Verholen, Jay Jhaveri, Shankar Srinivasa...> ;The Oncologist. 2024 Mar 4
Bladder cancer patient and provider perspectives on smoking cessation.
Matthew Mossanen, Angela B Smith, Nnamdi Onochie, Richard Matulewicz, Marc A Bjurlin, Adam S Kibel, Muhammad Abbas, Neal Shore, Stephanie Chisolm, Rick Bangs, Zara Coo...> ;Urologic Oncology. 2023 Nov 1
Join now to see all

Lectures

Real-World Clinical Outcomes with Radium-223 in Metastatic Castration-Resistant Prostate Cancer - Neal Shore
Large Urology Group Practice Association, Chicago, Illinois - 11/1/2012
Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-...
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

The EMBARK Trial: An Interview with Neal D. Shore, MDMay 19th, 2023
StockwatchMay 1st, 2023
Pfizer, Astellas Pharma' Xtandi Combo Therapy Cuts Risk of Metastasis, Death by 58 Percent in Prostate CancerMay 1st, 2023
Join now to see all